Abstract

Current influenza A virus (IAV) vaccines stimulate antibody responses that are directed against variable regions of the virus, and are therefore ineffective against divergent strains. As CD8+ T cells target the highly conserved, internal IAV proteins, they have the potential to increase heterosubtypic immunity. Early T‐cell priming events influence lasting memory, which is required for long‐term protection. However, the early responding, IAV‐specific cells are difficult to monitor because of their low frequencies. Here, we tracked the dissemination of endogenous IAV‐specific CD8+ T cells during the initial phases of the immune response following IAV infection. We exposed a significant population of recently activated, CD25+CD43+ IAV‐specific T cells that were not detected by tetramer staining. By tracking this population, we found that initial T‐cell priming occurred in the mediastinal lymph nodes, which gave rise to the most expansive IAV‐specific CD8+ T‐cell population. Subsequently, IAV‐specific CD8+ T cells dispersed to the bronchoalveolar lavage and blood, followed by spleen and liver, and finally to the lung. These data provide important insight into the priming and tissue dispersion of an endogenous CD8+ T‐cell response. Importantly, the CD25+CD43+ phenotype identifies an inclusive population of early responding CD8+ T cells, which may provide insight into TCR repertoire selection and expansion. A better understanding of this response is critical for designing improved vaccines that target CD8+ T cells.

Highlights

  • Current influenza A virus (IAV) vaccines are only effective against IAV subtypes included in the vaccine, and do not protect against slightly divergent or novel IAV strains

  • While the major IAV epitopes targeted by B cells vary between IAV subtypes, CD8+ T cells recognize epitopes from internal IAV proteins that are primarily conserved across multiple subtypes.[1]

  • By tracking the progression of CD25+CD43+ CD8+ T cells and tetramer-positive T cells, we showed that priming in the mediastinal lymph nodes (MLN) gave rise to the most expansive population of IAV-specific CD8+ T cells

Read more

Summary

Introduction

Current influenza A virus (IAV) vaccines are only effective against IAV subtypes included in the vaccine, and do not protect against slightly divergent or novel IAV strains. Developing a successful universal IAV vaccine that induces immunity to regions of IAV that are conserved between different subtypes is of utmost importance. An effective universal vaccine is likely to require both humoral and cellular responses. While the major IAV epitopes targeted by B cells vary between IAV subtypes, CD8+ T cells recognize epitopes from internal IAV proteins that are primarily conserved across multiple subtypes.[1]. Vaccines optimizing CD8+ T cell-mediated immunity may enhance protection against novel seasonal and pandemic IAVs. Mouse models of IAV pneumonia provide a welldeveloped experimental system for analyzing CD8+ T cell– mediated immunity.

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.